SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, ...

Antibody-drug conjugates are currently being investigated in more than 260 clinical trials.“It’s going to be the next novel ...

AstraZeneca (AZ) has announced that Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) has been recommended by ...

Despite challenges in the biopharma sector, Sophia Genetics SA (SOPH) showcases robust growth and strategic advancements in ...

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

From new payload linkers to artificial intelligence partnerships, advances in ADC pipelines push forward selective cancer therapies that minimize side effects.

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2025.

Guardant Health reports strong Q2 2025 results with 31% revenue growth, raised guidance, and momentum in oncology and Shield screening.

Portfolio Receipts was $727 million in the second quarter of 2025, an increase of 20% compared to $608 million in the second quarter of 2024, primarily driven by the same Royalty Receipts increases ...

The UK has been on a losing streak for too long. But the clouds seem to be lifting and Britons are beginning to win again.

The firm will evaluate the drug's safety and early efficacy in patients with advanced AKT1 E17K-mutant solid tumors.